Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) Stock Competitors & Peer Comparison
See VX1.DE's competitors and their performance on the XETRA and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for VX1.DE and its XETRA peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VX1.DE | €469.15 | -2.11% | 118.9B | 29.92 | €15.68 | N/A |
| DUL.DE | €200.70 | -0.69% | 26.9B | 69.10 | €2.91 | N/A |
| BM8.DE | €61.96 | -1.71% | 11.8B | 88.51 | €0.70 | N/A |
| EX9.DE | €32.28 | +1.22% | 9.2B | 35.47 | €0.91 | N/A |
| MOR.DE | €67.25 | -0.66% | 2.5B | -12.16 | -€5.53 | N/A |
| BIO3.DE | €32.20 | -0.62% | 1.6B | -51.11 | -€0.63 | N/A |
| BIO.DE | €40.00 | +2.04% | 1.4B | -63.49 | -€0.63 | N/A |
| IMU.DE | €5.17 | +0.00% | 1.1B | -9.22 | -€0.56 | N/A |
| GBY.DE | €5.05 | -3.81% | 884.7M | -4.38 | -€1.15 | N/A |
| 5CV.DE | €3.91 | +0.72% | 879.5M | 4.50 | €0.87 | N/A |
Stock Comparison
Alnylam Pharmaceuticals, Inc. (XETRA: DUL.DE)
VX1.DE vs DUL.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, DUL.DE has a market cap of 26.9B. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while DUL.DE trades at €200.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas DUL.DE's P/E ratio is 69.10. In terms of profitability, VX1.DE's ROE is +0.23%, compared to DUL.DE's ROE of +0.94%. Regarding short-term risk, VX1.DE is more volatile compared to DUL.DE. This indicates higher risk in terms of short-term price fluctuations for VX1.DE.Check DUL.DE's competition here
BioMarin Pharmaceutical Inc. (XETRA: BM8.DE)
VX1.DE vs BM8.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, BM8.DE has a market cap of 11.8B. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while BM8.DE trades at €61.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas BM8.DE's P/E ratio is 88.51. In terms of profitability, VX1.DE's ROE is +0.23%, compared to BM8.DE's ROE of +0.04%. Regarding short-term risk, VX1.DE is less volatile compared to BM8.DE. This indicates lower risk in terms of short-term price fluctuations for VX1.DE.Check BM8.DE's competition here
Exelixis, Inc. (XETRA: EX9.DE)
VX1.DE vs EX9.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, EX9.DE has a market cap of 9.2B. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while EX9.DE trades at €32.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas EX9.DE's P/E ratio is 35.47. In terms of profitability, VX1.DE's ROE is +0.23%, compared to EX9.DE's ROE of +0.40%. Regarding short-term risk, VX1.DE is less volatile compared to EX9.DE. This indicates lower risk in terms of short-term price fluctuations for VX1.DE.Check EX9.DE's competition here
MorphoSys AG (XETRA: MOR.DE)
VX1.DE vs MOR.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, MOR.DE has a market cap of 2.5B. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while MOR.DE trades at €67.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas MOR.DE's P/E ratio is -12.16. In terms of profitability, VX1.DE's ROE is +0.23%, compared to MOR.DE's ROE of -1.84%. Regarding short-term risk, VX1.DE is more volatile compared to MOR.DE. This indicates higher risk in terms of short-term price fluctuations for VX1.DE.Check MOR.DE's competition here
Biotest AG (XETRA: BIO3.DE)
VX1.DE vs BIO3.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, BIO3.DE has a market cap of 1.6B. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while BIO3.DE trades at €32.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas BIO3.DE's P/E ratio is -51.11. In terms of profitability, VX1.DE's ROE is +0.23%, compared to BIO3.DE's ROE of +0.05%. Regarding short-term risk, VX1.DE is more volatile compared to BIO3.DE. This indicates higher risk in terms of short-term price fluctuations for VX1.DE.Check BIO3.DE's competition here
Biotest AG (XETRA: BIO.DE)
VX1.DE vs BIO.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, BIO.DE has a market cap of 1.4B. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while BIO.DE trades at €40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas BIO.DE's P/E ratio is -63.49. In terms of profitability, VX1.DE's ROE is +0.23%, compared to BIO.DE's ROE of +0.05%. Regarding short-term risk, VX1.DE is less volatile compared to BIO.DE. This indicates lower risk in terms of short-term price fluctuations for VX1.DE.Check BIO.DE's competition here
ImmunoGen, Inc. (XETRA: IMU.DE)
VX1.DE vs IMU.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, IMU.DE has a market cap of 1.1B. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while IMU.DE trades at €5.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas IMU.DE's P/E ratio is -9.22. In terms of profitability, VX1.DE's ROE is +0.23%, compared to IMU.DE's ROE of -0.93%. Regarding short-term risk, VX1.DE is less volatile compared to IMU.DE. This indicates lower risk in terms of short-term price fluctuations for VX1.DE.Check IMU.DE's competition here
Sangamo Therapeutics, Inc. (XETRA: GBY.DE)
VX1.DE vs GBY.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, GBY.DE has a market cap of 884.7M. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while GBY.DE trades at €5.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas GBY.DE's P/E ratio is -4.38. In terms of profitability, VX1.DE's ROE is +0.23%, compared to GBY.DE's ROE of -1.85%. Regarding short-term risk, VX1.DE is more volatile compared to GBY.DE. This indicates higher risk in terms of short-term price fluctuations for VX1.DE.Check GBY.DE's competition here
CureVac N.V. (XETRA: 5CV.DE)
VX1.DE vs 5CV.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, 5CV.DE has a market cap of 879.5M. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while 5CV.DE trades at €3.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas 5CV.DE's P/E ratio is 4.50. In terms of profitability, VX1.DE's ROE is +0.23%, compared to 5CV.DE's ROE of +0.29%. Regarding short-term risk, VX1.DE is less volatile compared to 5CV.DE. This indicates lower risk in terms of short-term price fluctuations for VX1.DE.Check 5CV.DE's competition here
Ergomed plc (XETRA: 2EM.DE)
VX1.DE vs 2EM.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, 2EM.DE has a market cap of 586M. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while 2EM.DE trades at €11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas 2EM.DE's P/E ratio is 34.38. In terms of profitability, VX1.DE's ROE is +0.23%, compared to 2EM.DE's ROE of +0.20%. Regarding short-term risk, VX1.DE is more volatile compared to 2EM.DE. This indicates higher risk in terms of short-term price fluctuations for VX1.DE.Check 2EM.DE's competition here
Formycon AG (XETRA: FYB.DE)
VX1.DE vs FYB.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, FYB.DE has a market cap of 333M. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while FYB.DE trades at €18.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas FYB.DE's P/E ratio is -13.35. In terms of profitability, VX1.DE's ROE is +0.23%, compared to FYB.DE's ROE of -0.06%. Regarding short-term risk, VX1.DE is less volatile compared to FYB.DE. This indicates lower risk in terms of short-term price fluctuations for VX1.DE.Check FYB.DE's competition here
Newron Pharmaceuticals S.p.A. (XETRA: NP5.DE)
VX1.DE vs NP5.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, NP5.DE has a market cap of 193.8M. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while NP5.DE trades at €9.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas NP5.DE's P/E ratio is -6.50. In terms of profitability, VX1.DE's ROE is +0.23%, compared to NP5.DE's ROE of +2.59%. Regarding short-term risk, VX1.DE is less volatile compared to NP5.DE. This indicates lower risk in terms of short-term price fluctuations for VX1.DE.Check NP5.DE's competition here
4SC AG (XETRA: VSC.DE)
VX1.DE vs VSC.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, VSC.DE has a market cap of 150.7M. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while VSC.DE trades at €2.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas VSC.DE's P/E ratio is -7.27. In terms of profitability, VX1.DE's ROE is +0.23%, compared to VSC.DE's ROE of -0.90%. Regarding short-term risk, VX1.DE is more volatile compared to VSC.DE. This indicates higher risk in terms of short-term price fluctuations for VX1.DE.Check VSC.DE's competition here
InflaRx N.V. (XETRA: IF0.DE)
VX1.DE vs IF0.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, IF0.DE has a market cap of 129.9M. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while IF0.DE trades at €2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas IF0.DE's P/E ratio is -2.43. In terms of profitability, VX1.DE's ROE is +0.23%, compared to IF0.DE's ROE of -0.45%. Regarding short-term risk, VX1.DE is more volatile compared to IF0.DE. This indicates higher risk in terms of short-term price fluctuations for VX1.DE.Check IF0.DE's competition here
4basebio PLC (XETRA: 88Q.DE)
VX1.DE vs 88Q.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, 88Q.DE has a market cap of 103M. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while 88Q.DE trades at €6.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas 88Q.DE's P/E ratio is -4.94. In terms of profitability, VX1.DE's ROE is +0.23%, compared to 88Q.DE's ROE of -3.19%. Regarding short-term risk, VX1.DE is more volatile compared to 88Q.DE. This indicates higher risk in terms of short-term price fluctuations for VX1.DE.Check 88Q.DE's competition here
Heidelberg Pharma AG (XETRA: HPHA.DE)
VX1.DE vs HPHA.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, HPHA.DE has a market cap of 100.6M. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while HPHA.DE trades at €2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas HPHA.DE's P/E ratio is -3.04. In terms of profitability, VX1.DE's ROE is +0.23%, compared to HPHA.DE's ROE of +2.01%. Regarding short-term risk, VX1.DE is less volatile compared to HPHA.DE. This indicates lower risk in terms of short-term price fluctuations for VX1.DE.Check HPHA.DE's competition here
BRAIN Biotech AG (XETRA: BNN.DE)
VX1.DE vs BNN.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, BNN.DE has a market cap of 59.6M. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while BNN.DE trades at €2.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas BNN.DE's P/E ratio is -4.14. In terms of profitability, VX1.DE's ROE is +0.23%, compared to BNN.DE's ROE of +5.91%. Regarding short-term risk, VX1.DE is less volatile compared to BNN.DE. This indicates lower risk in terms of short-term price fluctuations for VX1.DE.Check BNN.DE's competition here
FamiCord AG (XETRA: V3V.DE)
VX1.DE vs V3V.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, V3V.DE has a market cap of 47.2M. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while V3V.DE trades at €2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas V3V.DE's P/E ratio is -6.16. In terms of profitability, VX1.DE's ROE is +0.23%, compared to V3V.DE's ROE of -0.95%. Regarding short-term risk, VX1.DE is less volatile compared to V3V.DE. This indicates lower risk in terms of short-term price fluctuations for VX1.DE.Check V3V.DE's competition here
Clovis Oncology, Inc. (XETRA: C6O.DE)
VX1.DE vs C6O.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, C6O.DE has a market cap of 13.2M. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while C6O.DE trades at €0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas C6O.DE's P/E ratio is -0.05. In terms of profitability, VX1.DE's ROE is +0.23%, compared to C6O.DE's ROE of +1.21%. Regarding short-term risk, VX1.DE is less volatile compared to C6O.DE. This indicates lower risk in terms of short-term price fluctuations for VX1.DE.Check C6O.DE's competition here
co.don AG (XETRA: CNW.DE)
VX1.DE vs CNW.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, CNW.DE has a market cap of 6.5M. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while CNW.DE trades at €0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas CNW.DE's P/E ratio is -0.44. In terms of profitability, VX1.DE's ROE is +0.23%, compared to CNW.DE's ROE of -0.49%. Regarding short-term risk, VX1.DE is less volatile compared to CNW.DE. This indicates lower risk in terms of short-term price fluctuations for VX1.DE.Check CNW.DE's competition here
Medigene AG (XETRA: MDG1.DE)
VX1.DE vs MDG1.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, MDG1.DE has a market cap of 2M. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while MDG1.DE trades at €0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas MDG1.DE's P/E ratio is -0.11. In terms of profitability, VX1.DE's ROE is +0.23%, compared to MDG1.DE's ROE of -0.56%. Regarding short-term risk, VX1.DE is less volatile compared to MDG1.DE. This indicates lower risk in terms of short-term price fluctuations for VX1.DE.Check MDG1.DE's competition here
CytoTools AG (XETRA: T5O.DE)
VX1.DE vs T5O.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, T5O.DE has a market cap of 164.4K. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while T5O.DE trades at €0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas T5O.DE's P/E ratio is -0.25. In terms of profitability, VX1.DE's ROE is +0.23%, compared to T5O.DE's ROE of -1.91%. Regarding short-term risk, VX1.DE is less volatile compared to T5O.DE. This indicates lower risk in terms of short-term price fluctuations for VX1.DE.Check T5O.DE's competition here
co.don AG (XETRA: CNWK.DE)
VX1.DE vs CNWK.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, CNWK.DE has a market cap of 0. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while CNWK.DE trades at €2.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas CNWK.DE's P/E ratio is -5.82. In terms of profitability, VX1.DE's ROE is +0.23%, compared to CNWK.DE's ROE of -0.86%. Regarding short-term risk, VX1.DE is less volatile compared to CNWK.DE. This indicates lower risk in terms of short-term price fluctuations for VX1.DE.Check CNWK.DE's competition here
Alexion Pharmaceuticals, Inc. (XETRA: AXP.DE)
VX1.DE vs AXP.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, AXP.DE has a market cap of 0. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while AXP.DE trades at €153.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas AXP.DE's P/E ratio is 59.63. In terms of profitability, VX1.DE's ROE is +0.23%, compared to AXP.DE's ROE of +0.05%. Regarding short-term risk, VX1.DE is more volatile compared to AXP.DE. This indicates higher risk in terms of short-term price fluctuations for VX1.DE.Check AXP.DE's competition here
Cocrystal Pharma Inc (DUS: 8CC1.DU)
VX1.DE vs 8CC1.DU Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, 8CC1.DU has a market cap of 0. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while 8CC1.DU trades at €0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas 8CC1.DU's P/E ratio is N/A. In terms of profitability, VX1.DE's ROE is +0.23%, compared to 8CC1.DU's ROE of N/A. Regarding short-term risk, VX1.DE is less volatile compared to 8CC1.DU. This indicates lower risk in terms of short-term price fluctuations for VX1.DE.Check 8CC1.DU's competition here
Mologen AG (XETRA: MGNK.DE)
VX1.DE vs MGNK.DE Comparison October 2026
Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VX1.DE stands at 118.9B. In comparison, MGNK.DE has a market cap of 0. Regarding current trading prices, VX1.DE is priced at €469.15 on the XETRA, while MGNK.DE trades at €0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VX1.DE currently has a P/E ratio of 29.92, whereas MGNK.DE's P/E ratio is N/A. In terms of profitability, VX1.DE's ROE is +0.23%, compared to MGNK.DE's ROE of +4.09%. Regarding short-term risk, VX1.DE is less volatile compared to MGNK.DE. This indicates lower risk in terms of short-term price fluctuations for VX1.DE.Check MGNK.DE's competition here